Navigation Links
Gene Variant Boosts Risk of Severe Diabetic Eye, Kidney Diseases
Date:5/8/2008

Finding suggests careful use of blood-boosting drugs in anemia patients

THURSDAY, May 8 (HealthDay News) -- A gene called erythropoietin (EPO) is linked to severe diabetic eye and kidney diseases, a new study finds.

The study, led by a researcher at the John A. Moran Eye Center at the University of Utah, included 1,618 people with proliferative diabetic retinopathy (PDR) and end-stage renal disease (ESRD) and 954 diabetic patients without any eye or kidney disease.

PDR is the most common cause of legal blindness in working-age adults in the United States, accounting for 10 percent of new onset blindness overall. Diabetes is the leading cause of ESRD.

The researchers found that people with a copy of mutant EPO gene have an increased risk of developing PDR and ESRD.

"We know that the development of PDR and ESRD in diabetic patients can be inherited. Although genetic factors are known to be important in the susceptibility [or resistance] to these complications, until now, the genes involved have been mostly unknown," study leader Dr. Kang Zhang, director of the division of ophthalmic genetics at the Moran Eye Center and an associate professor of ophthalmology and visual sciences, said in a prepared statement.

The study was published online May 5 in the Proceedings of the National Academy of Sciences.

This finding may affect the use of EPO in treating patients with anemia, Zhang said.

EPO is used extensively to help in the production of red blood cells when treating patients with anemia resulting from renal failure or chemotherapy. In the United States, erythropoietin represents one of the largest single drug expenses for the Center for Medicare & Medicaid Services, approximately one billion dollars per year," Zhang said.

"Patients with anemia due to chronic renal disease [many of whom have diabetes] who receive frequent dosing of EPO to maintain higher hemoglobin levels have a higher rate of cardiovascular complications than patients who maintain a lower hemoglobin level. A similar effect of EPO on accelerating the decline of kidney function had been suggested by earlier studies. Our study suggests that caution may be warranted when maintaining higher hemoglobin concentration using exogenous EPO treatment in diabetic patients, as it might accelerate progression to PDR and ESRD."

Study co-author Dr. Dean Li, from the Program in Human Molecular Biology and Genetics at the University of Utah, added: "Though there is no proven pharmacologic treatment for diabetic vascular eye diseases, inhibiting the growth of unwanted blood vessel growth using antibodies directed against vascular endothelial growth factor [anti-VEGF therapy] has been advocated. This genetic study suggests that future therapeutic strategies need to consider blunting the effects of erythropoietin in addition, or as an alternative, to an anti-VEGF strategy."

More information

The U.S. National Eye Institute has more about diabetic eye disease.



-- Robert Preidt



SOURCE: University of Utah, news release, May 5, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Gene Variant Boosts Risk for Stress-Related Ischemia
2. Gene Variant Protects Black Heart Failure Patients
3. Gene Variants Linked to Lung Cancer Identified
4. Gene Variants Can Predict Threat of Heart Disease
5. Gene variant predicts medication response in patients with alcohol dependence
6. Gene variant linked to moderated symptoms of beta-thalassemia
7. Gene Variant Tied to More Aggressive Prostate Cancer
8. Gene Variant Doubles Risk of Prostate Cancer in Black Men
9. Scientists discover genetic variant associated with prostate cancer in African Americans
10. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
11. Obesity-Related Inflammation Boosts Heart Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 29, 2017 , ... Full Contact K9, an Atlanta-based dog services provider, has ... that assists dog owners in creating legally-enforceable pet trusts for their canine companions. ... step to protect their new companion. Says Evan Dunbar, CEO of Full Contact K9, ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, ... school and college students who have participated in the program every summer. The ... now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells ... for attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, ... been recognized as the visionary leader in the training of physicians, scientists, and ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from Guardian’s ... face in trying to balance both short-term and long-term benefits demands. Are ... the growing complexity, companies are finding that the short-term strategies used to control ...
(Date:3/29/2017)... (PRWEB) , ... March 29, ... ... Manufacturer Alliance (GRMA) is growing as it continues developing an ANSI-approved, consensus-based ... industry. The organization, which plans to publish the first ANSI-approved GMP standard ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Zynex (OTCQB: ZYXI), an ... sale of non-invasive medical devices for pain management, stroke ... it will host the Company,s 2016 full-year investor webcast ... Time.) The Company expects to file its ... ...
(Date:3/29/2017)... N.J. , March 29, 2017  Glenmark ... results for GSP 301, an investigational fixed-dose combination ... (665 mcg) administered twice-daily as a nasal spray ... rhinitis. These results are from a recently completed ... of GSP 301 combination therapy versus mometasone, olopatadine ...
(Date:3/29/2017)... -- Maxor National Pharmacy Services, LLC ("Maxor"), a leading pharmacy ... Leah Bailey as General Counsel.  Bailey will serve as ... With more than 13 years of experience in ... health care, Bailey joins the Maxor team coming from ... the PBM, Specialty, and Mail Order business areas on ...
Breaking Medicine Technology: